These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 12019105

  • 1. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis.
    Tsenova L, Mangaliso B, Muller G, Chen Y, Freedman VH, Stirling D, Kaplan G.
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1887-95. PubMed ID: 12019105
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system.
    Tsenova L, Bergtold A, Freedman VH, Young RA, Kaplan G.
    Proc Natl Acad Sci U S A; 1999 May 11; 96(10):5657-62. PubMed ID: 10318940
    [Abstract] [Full Text] [Related]

  • 5. Adjunctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role.
    Schoeman JF, Springer P, Ravenscroft A, Donald PR, Bekker LG, van Rensburg AJ, Hanekom WA, Haslett PA, Kaplan G.
    J Child Neurol; 2000 Aug 11; 15(8):497-503. PubMed ID: 10961786
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preclinical models to optimize treatment of tuberculous meningitis - A systematic review.
    Litjens CHC, Aarnoutse RE, Te Brake LHM.
    Tuberculosis (Edinb); 2020 May 11; 122():101924. PubMed ID: 32501258
    [Abstract] [Full Text] [Related]

  • 11. Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.
    Tucker EW, Pieterse L, Zimmerman MD, Udwadia ZF, Peloquin CA, Gler MT, Ganatra S, Tornheim JA, Chawla P, Caoili JC, Ritchie B, Jain SK, Dartois V, Dooley KE.
    Antimicrob Agents Chemother; 2019 Oct 11; 63(10):. PubMed ID: 31383662
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinicoradiologic response of neurologic tuberculous mass lesions in children treated with thalidomide.
    van Toorn R, du Plessis AM, Schaaf HS, Buys H, Hewlett RH, Schoeman JF.
    Pediatr Infect Dis J; 2015 Feb 11; 34(2):214-8. PubMed ID: 25741973
    [Abstract] [Full Text] [Related]

  • 14. Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis.
    Burroughs MH, Tsenova-Berkova L, Sokol K, Ossig J, Tuomanen E, Kaplan G.
    Microb Pathog; 1995 Oct 11; 19(4):245-55. PubMed ID: 8825912
    [Abstract] [Full Text] [Related]

  • 15. The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports.
    Roberts MT, Mendelson M, Meyer P, Carmichael A, Lever AM.
    J Infect; 2003 Oct 11; 47(3):251-5. PubMed ID: 12963389
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.